Initial trials using olaparib, a PARP inhibitor, for treatment of metastatic, castration-resistant prostate cancer showed an impressive response rate among patients with PVs in the HR repair pathway, including patients with ATM deficiency [107,108,109]. The gene discussed is ATM; the disease is prostate cancer.